Monopteros Therapeutics Overview

  • Founded
  • 2019
Founded
  • Status
  • Private
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $20M
Latest Deal Amount
  • Investors
  • 1

Monopteros Therapeutics General Information

Description

Developer of inhibitor intended to focus on reprogramming of regulatory T cells. The company works on a treatment to reprogram T cells in the tumor microenvironment to jump-start an immune attack in cancer patients who otherwise would not respond to checkpoint inhibitors and also provides immunotherapy, which harnesses the power of the immune system to recognize and destroy cancer, thereby enabling cancer patients to have a lasting, life-changing immune response with solid tumors.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • 4 Gap Head Road
  • Rockport, MA 01966-1908
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Monopteros Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 22-Apr-2021 $20M 0000 0000 Completed Startup
To view Monopteros Therapeutics’s complete valuation and funding history, request access »

Monopteros Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
To view Monopteros Therapeutics’s complete cap table history, request access »

Monopteros Therapeutics Executive Team (2)

Name Title Board Seat Contact Info
Arthur DeCillis MD Chief Medical Officer
Peter Keller Chief Executive Officer & Board Member
To view Monopteros Therapeutics’s complete executive team members history, request access »

Monopteros Therapeutics Board Members (5)

Name Representing Role Since
Debasish Roychowdhury MD Self Board Member 000 0000
Francesco Rubertis Ph.D Self Board Member 000 0000
Peter Keller Self Chief Executive Officer & Board Member 000 0000
Shyam Masrani Self Board Member 000 0000
Ulrich von Andrian MD Monopteros Therapeutics Board Member 000 0000
To view Monopteros Therapeutics’s complete board members history, request access »

Monopteros Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Medicxi Venture Capital Minority 000 0000 000000 0
To view Monopteros Therapeutics’s complete investors history, request access »